Revolade Tablets Specified Drug-use Survey
Recruiting
- Conditions
- Aplastic Anemia
- Interventions
- Other: eltrombopag
- First Posted Date
- 2024-03-01
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 10
- Registration Number
- NCT06287268
- Locations
- 🇯🇵
Novartis Investigative Site, Saitama, Japan
Specified Drug-use Survey of Leqvio for s.c. Injection.
Active, not recruiting
- Conditions
- HypercholesterolaemiaFamilial Hypercholesterolaemia
- Interventions
- Other: inclisiran
- First Posted Date
- 2024-02-23
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 583
- Registration Number
- NCT06275724
- Locations
- 🇯🇵
Novartis Investigative Site, Yamagata, Japan
Real-World HRU and Costs in DLBCL Pts With Tisa-cel and Axi-cel, a Medicare Study.
Completed
- Conditions
- Diffuse Large B-cell Lymphoma
- First Posted Date
- 2024-02-21
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 613
- Registration Number
- NCT06271369
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD
Phase 3
Recruiting
- Conditions
- Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 400
- Registration Number
- NCT06267560
- Locations
- 🇺🇸
Synexus Clinical Research Advantage, Birmingham, Alabama, United States
🇺🇸Parkway Medical Center, Birmingham, Alabama, United States
🇺🇸Optimal Research LLC, Huntsville, Alabama, United States
Special Drug Use-results Surveillance of Tafinlar/Mekinist
Recruiting
- Conditions
- BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor
- Interventions
- Drug: Tafinlar/Mekinist
- First Posted Date
- 2024-02-16
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 110
- Registration Number
- NCT06262919
- Locations
- 🇯🇵
Novartis Investigative Site, Yamagata, Japan
A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical Practice
Completed
- Conditions
- Relapsing Forms of Multiple Sclerosis
- Interventions
- Other: ofatumumab
- First Posted Date
- 2024-02-09
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 311
- Registration Number
- NCT06251986
- Locations
- 🇪🇸
Novartis Investigative Site, Zaragoza, Spain
Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes Among Patients With BRAF-Positive Metastatic Melanoma
Completed
- Conditions
- BRAF-positive Metastatic Melanoma
- First Posted Date
- 2024-02-09
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 785
- Registration Number
- NCT06251934
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
Phase 1
Recruiting
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2024-02-08
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 58
- Registration Number
- NCT06247995
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸Uni Of TX MD Anderson Cancer Cntr, Houston, Texas, United States
A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Healthy Volunteers in Japan
Phase 3
Completed
- Conditions
- Neuroendocrine Neoplasms
- Interventions
- Drug: 68Ge/68Ga Generator
- First Posted Date
- 2024-02-05
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 71
- Registration Number
- NCT06240741
- Locations
- 🇯🇵
Novartis Investigative Site, Kyoto, Japan
Migraine Survey in Gulf Region
Recruiting
- Conditions
- Migraine
- Interventions
- Other: erenumab
- First Posted Date
- 2024-02-01
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT06237062
- Locations
- 🇦🇪
Novartis Investigative Site, Sharjah, United Arab Emirates
© Copyright 2025. All Rights Reserved by MedPath